In ANCA-associated vasculitis, excessive inflammatory reactions lead to pulmonary hemorrhages that can be fatal if left untreated. Researchers have deciphered a mechanism in mice and patients that ...

Bacterial DNA Motifs Trigger ANCA Production in ANCA-Associated Vasculitis in Remission Tadema H, Abdulahad WH, Lepse N, Stegeman CA, Kallenberg CG, Heeringa P Rheumatology (Oxford). 2011;50:689-696 ...

Despite a stable incidence of ANCA-associated vasculitis in southern Sweden, the prevalence of the condition has increased, according to a population-based study spanning a 23-year period. From ...

This proof-of-concept of C5A antagonism in ANCA vasculitis led to the ADVOCATE trial, which, in turn, led to approval of avacopan for this indication. “Patients on avacopan had less relapses ...

Myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis is a systemic condition affecting the small vessels with production of MPO-ANCA in serum. It has been suggested ...

Vasculitis can be classified into several types based on the size of the blood vessels affected and the underlying cause. ANCA-Associated Vasculitis This includes granulomatosis with polyangiitis ...

The Kidney Disease: Improving Global Outcomes organization has published a new guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The 46-page ...

Nearly all children with ANCA-associated vasculitis demonstrate active kidney disease at diagnosis, and their renal function status is strongly predictive of outcomes 1 year later, according to ...

JAK Inhibitor Succeeds in Refractory Vasculitis — Seven of 11 patients respond after failing multiple previous meds by John Gever, Contributing Writer, MedPage Today March 16, 2023 ...

Study Results Median follow-up was 4.1 years from study entry. Throughout the study, 5 of 58 patients in the B-cell arm and 14 of 57 in the ANCA arm had relapses. According to Kaplan-Meier ...

New findings from a Japanese study suggest a possible link between COVID-19 mRNA vaccination and ANCA-associated vasculitis (AAV). From February 2021 to February 2023, Japan successfully completed ...